<?xml version="1.0" encoding="UTF-8" standalone="yes"?><trialResultsOutput hits="1" offset="0" totalResults="1"><Filters total="48"><Filter label="Trial Technologies" name="trialTechnologies" total="4"><FilterOption id="585" count="1" label="Oral formulation"/><FilterOption id="762" count="1" label="Small molecule therapeutic"/><FilterOption id="595" count="1" label="Tablet formulation"/><FilterOption id="806" count="1" label="Weekly dosing"/></Filter><Filter label="Indications" name="indications" total="1"><FilterOption id="246" count="1" label="Osteoporosis"/></Filter><Filter label="Endpoint Index" name="trialEndpointIndex" total="3"><FilterOption id="13796" count="1" label="Osteoporosis - Assessment of Markers of Bone/Cartilage/Collagen Turnover - Urine Type-I Collagen N-telopeptide/Creatinine (NTX / Cr)"/><FilterOption id="13835" count="1" label="Osteoporosis - Assessment of Pharmacokinetic/Pharmacodynamic Parameters"/><FilterOption id="13840" count="1" label="Osteoporosis - Assessment of adverse events"/></Filter><Filter label="Trial Drug Phase Highest" name="trialDrugPhaseHighest" total="1"><FilterOption id="DX" count="1" label="Discontinued"/></Filter><Filter label="Trial Company Sponsor" name="trialCompaniesSponsor" total="1"><FilterOption id="1059823" count="1" label="Merck Sharp &amp; Dohme Corp"/></Filter><Filter label="Trial Recruitment Status" name="trialRecruitmentStatus" total="1"><FilterOption id="6" count="1" label="Terminated"/></Filter><Filter label="Trial Commercially Significant" name="trialIsCommerciallySignificant" total="1"><FilterOption id="NO" count="1" label="No"/></Filter><Filter label="Trial Indications Pioneer" name="trialIndicationsPioneer" total="0"/><Filter label="Registry Id" name="trialRegistries" total="2"><FilterOption id="1000" count="1" label="CT.gov"/><FilterOption id="1001" count="1" label="EudraCT"/></Filter><Filter label="Trial Reason for Discontinuation" name="trialReasonForDiscontinuation" total="1"><FilterOption id="2" count="1" label="Not Reported"/></Filter><Filter label="Active Controls" name="trialActiveControls" total="0"/><Filter label="Exclusion Criteria Index" name="trialExclusionCriteriaIndex" total="13"><FilterOption id="10248" count="1" label="Osteoporosis - Subjects co-morbid with endocrine/metabolic diseases/disorders"/><FilterOption id="10245" count="1" label="Osteoporosis - Subjects co-morbid with gastrointestinal diseases/disorders"/><FilterOption id="10250" count="1" label="Osteoporosis - Subjects co-morbid with inflammatory disorders"/><FilterOption id="10242" count="1" label="Osteoporosis - Subjects with Co-morbid Conditions - Subjects with central nervous system diseases/disorders"/><FilterOption id="10249" count="1" label="Osteoporosis - Subjects with Co-morbid Conditions - Subjects with premalignant/malignant condition"/><FilterOption id="10241" count="1" label="Osteoporosis - Subjects with Co-morbid Conditions"/><FilterOption id="10815" count="1" label="Osteoporosis - Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy - Subjects with history/scheduled to receive steroids"/><FilterOption id="10821" count="1" label="Osteoporosis - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of estrogen replacement therapy"/><FilterOption id="10267" count="1" label="Osteoporosis - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of treatment with bisphosphonates"/><FilterOption id="10817" count="1" label="Osteoporosis - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of vitamin D therapy"/><FilterOption id="10819" count="1" label="Osteoporosis - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of/scheduled to receive hormone replacement therapy"/><FilterOption id="10263" count="1" label="Osteoporosis - Subjects with Hypersensitivity/Contraindications to Drugs/Excipients"/><FilterOption id="10268" count="1" label="Osteoporosis - Subjects with history of/scheduled to receive therapy for other indication"/></Filter><Filter label="Trial Date Enrollment End By Month" name="trialDateEnrollmentEndByMonth" total="0"/><Filter label="Funder Type" name="trialFunderType" total="1"><FilterOption id="CMP" count="1" label="Company"/></Filter><Filter label="Trial Region" name="trialRegions" total="4"><FilterOption id="EAPO" count="1" label="East Asia &amp; Pacific Ocean"/><FilterOption id="EEUR" count="1" label="Eastern Europe"/><FilterOption id="NSWE" count="1" label="Northern, Southern &amp; Western Europe"/><FilterOption id="USCA" count="1" label="US &amp; Canada"/></Filter><Filter label="Patient Segment Index" name="trialPatientSegmentIndex" total="1"><FilterOption id="7653" count="1" label="Osteoporosis - Subjects at risk of developing disease"/></Filter><Filter label="Primary Completion Filter by Month" name="trialPrimaryCompletionDateByMonth" total="1"><FilterOption count="1" label="201607"/></Filter><Filter label="Trial Country" name="trialCountries" total="7"><FilterOption id="CA" count="1" label="Canada"/><FilterOption id="FI" count="1" label="Finland"/><FilterOption id="IT" count="1" label="Italy"/><FilterOption id="MD" count="1" label="Moldova, Republic of"/><FilterOption id="KR" count="1" label="South Korea"/><FilterOption id="GB" count="1" label="UK"/><FilterOption id="US" count="1" label="US"/></Filter><Filter label="Trial Patient Selection" name="trialTermsPatientSelection" total="3"><FilterOption id="EAADL" count="1" label="Adolescents (13-17 yrs)"/><FilterOption id="EACHI" count="1" label="Children (6-12 yrs)"/><FilterOption id="EAYAD" count="1" label="Young Adults (18-44 yrs)"/></Filter><Filter label="Trial Terms Design" name="trialTermsDesign" total="6"><FilterOption id="SSTINV" count="1" label="Interventional"/><FilterOption id="SIMMBD" count="1" label="Multiple Blind"/><FilterOption id="SISPRL" count="1" label="Parallel Assignment"/><FilterOption id="SICPLC" count="1" label="Placebo Control"/><FilterOption id="SIARND" count="1" label="Randomized"/><FilterOption id="SIPTRE" count="1" label="Treatment"/></Filter><Filter label="Trial Source" name="trialSources" total="1"><FilterOption id="CTGOV" count="1" label="ClinicalTrials.gov only"/></Filter><Filter label="Trial Actions Secondary Interventions Primary" name="trialActionsSecondaryInterventionsPrimary" total="2"><FilterOption id="1545" count="1" label="Anticancer"/><FilterOption id="89" count="1" label="Bone resorption inhibitor"/></Filter><Filter label="Trial Endpoint Achieved" name="trialEndpointsAchieved" total="0"/><Filter label="Endpoint Index Secondary" name="trialEndpointIndexSecondary" total="1"><FilterOption id="13796" count="1" label="Osteoporosis - Assessment of Markers of Bone/Cartilage/Collagen Turnover - Urine Type-I Collagen N-telopeptide/Creatinine (NTX / Cr)"/></Filter><Filter label="Biomarker" name="trialBiomarkerNames" total="1"><FilterOption id="13540" count="1" label="N-terminal type I collagen telopeptide/Creatinine ratio"/></Filter><Filter label="Trial Terms Endpoint" name="trialTermsEndpoint" total="3"><FilterOption id="SIEPCD" count="1" label="Pharmacodynamics"/><FilterOption id="SIEPCK" count="1" label="Pharmacokinetics"/><FilterOption id="SIESFT" count="1" label="Safety"/></Filter><Filter label="Trial Interventions Primary In Regimen Name Display" name="trialInterventionsPrimaryInRegimenNameDisplay" total="0"/><Filter label="Trial Document Source" name="trialDocumentSource" total="0"/><Filter label="Trial Interventions Primary Alone Name Display" name="trialInterventionsPrimaryAloneNameDisplay" total="1"><FilterOption id="52614" count="1" label="odanacatib"/></Filter><Filter label="Trial Interventions Control In Regimen Name Display" name="trialInterventionsControlInRegimenNameDisplay" total="0"/><Filter label="Trial Category" name="trialCategory" total="1"><FilterOption id="4" count="1" label="Small molecule"/></Filter><Filter label="Trial Outcome Available" name="trialOutcomesAvailable" total="1"><FilterOption id="NO" count="1" label="No"/></Filter><Filter label="Trial Actions Primary Interventions Primary" name="trialActionsPrimaryInterventionsPrimary" total="1"><FilterOption id="1901" count="1" label="Cathepsin K inhibitor"/></Filter><Filter label="Trial Company Collaborator" name="trialCompaniesCollaborator" total="0"/><Filter label="Trial Actions Secondary Interventions Control" name="trialActionsSecondaryInterventionsControl" total="0"/><Filter label="Biomarker Type" name="trialBiomarkerTypes" total="1"><FilterOption id="32" count="1" label="Biochemical"/></Filter><Filter label="Biomarker Role" name="trialBiomarkerRoles" total="1"><FilterOption id="695863716" count="1" label="Therapeutic effect marker"/></Filter><Filter label="Interventions" name="trialInterventions" total="1"><FilterOption id="52614" count="1" label="odanacatib"/></Filter><Filter label="Endpoint Index Primary" name="trialEndpointIndexPrimary" total="2"><FilterOption id="13835" count="1" label="Osteoporosis - Assessment of Pharmacokinetic/Pharmacodynamic Parameters"/><FilterOption id="13840" count="1" label="Osteoporosis - Assessment of adverse events"/></Filter><Filter label="Sponsors/Collaborators" name="trialCompanies" total="1"><FilterOption id="1059823" count="1" label="Merck Sharp &amp; Dohme Corp"/></Filter><Filter label="Last Changed Date By Day" name="trialDateChangeLastByDay" total="1"><FilterOption count="1" label="2019-05-23"/></Filter><Filter label="Trial Date End By Month" name="trialDateEndByMonth" total="0"/><Filter label="Trial Date Start By Month" name="trialDateStartByMonth" total="1"><FilterOption count="1" label="201303"/></Filter><Filter label="Trial Phase" name="trialPhase" total="1"><FilterOption id="C1" count="1" label="Phase 1 Clinical"/></Filter><Filter label="Inclusion Criteria Index" name="trialInclusionCriteriaIndex" total="3"><FilterOption id="8680" count="1" label="Osteoporosis - Subjects at Risk of Developing Disease"/><FilterOption id="13288" count="1" label="Osteoporosis - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of steroid therapy"/><FilterOption id="8701" count="1" label="Osteoporosis - Subjects with Normal/Acceptable Clinical Assessments"/></Filter><Filter label="Trial Interventions Control Alone Name Display" name="trialInterventionsControlAloneNameDisplay" total="0"/><Filter label="Trial Actions Primary Interventions Control" name="trialActionsPrimaryInterventionsControl" total="0"/><Filter label="Trial Indications Adverse" name="trialIndicationsAdverse" total="0"/></Filters><SearchResults><Trial Id="88788"><Indications><Indication>Osteoporosis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Cathepsin K inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Bone resorption inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology><Technology>Weekly dosing</Technology></Technologies><CompaniesSponsor><Company>Merck Sharp &amp; Dohme Corp</Company></CompaniesSponsor><Countries><Country>Finland</Country><Country>UK</Country><Country>Canada</Country><Country>Moldova, Republic of</Country><Country>US</Country><Country>South Korea</Country><Country>Italy</Country></Countries><DateChangeLast>2019-05-23T00:00:00Z</DateChangeLast><DateStart>2013-03-12T00:00:00Z</DateStart><Identifiers><Identifier>0822-066</Identifier><Identifier>2012-003414-14</Identifier><Identifier>MK-0822-066</Identifier><Identifier>NCT01630616</Identifier><Identifier>P/227/2013</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>odanacatib alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>19</PatientCountEnrollment><Phase>Phase 1 Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Not Reported</Reason></ReasonForTrialDiscontinuation><Teaser>The purpose of this study is to assess the safety, tolerability, pharmacodynamics, and pharmacokinetics of single-doses of odanacatib in mature adolescents and young adults who are currently receiving glucocorticoid therapy. The primary hypotheses for the study are that a single-dose of odanacatib is well tolerated in mature adolescents and following single dose administration of odanacatib 50 mg, there is no clinically important difference in AUC0 to inf between mature adolescents and young</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Osteoporosis - Assessment of Markers of Bone/Cartilage/Collagen Turnover - Urine Type-I Collagen N-telopeptide/Creatinine (NTX / Cr)</EndpointIndex><EndpointIndex>Osteoporosis - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Osteoporosis - Assessment of adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>A Study of Odanacatib When Administered to Adolescents and Young Adults Treated With Glucocorticoids</TitleDisplay><PatientSegmentTerms><PatientSegment>Osteoporosis - Subjects at risk of developing disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>N-terminal type I collagen telopeptide/Creatinine ratio</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2016-07-14T00:00:00Z</PrimaryCompletionDate><NumberOfSites>9</NumberOfSites><ContactNames><Name>Aubrey Stoch</Name><Name>AubreyÂ Stoch</Name><Name>Cem Ozesen</Name><Name>Divisione Ricerca Clinica</Name><Name>Medical Director</Name><Name>Paul Robinson</Name><Name>Tatyana Gots</Name></ContactNames></Trial></SearchResults></trialResultsOutput>